Fructose-1,6-bisphosphatase Inhibitors: A review of recent (2000-2017) advances and structure-activity relationship studies

Sarbjit Singh, Dipesh S. Harmalkar, Yongseok Choi, Kyeong Lee

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Diabetes mellitus, commonly referred to as diabetes, is the 8th leading cause of death worldwide. As of 2015, approximately 415 million people were estimated to be diabetic worldwide, type 2 diabetes being the most common accounting for approximately 90-95% of all diagnosed cases with increasing prevalence. Fructose-1,6-bisphosphatase is one of the important therapeutic targets recently discovered to treat this chronic disease. In this focused review, we have highlighted recent advances and structure-activity relationship studies in the discovery and development of different fructose-1,6-bisphosphatase inhibitors reported since the year 2000.

Original languageEnglish
Pages (from-to)5542-5563
Number of pages22
JournalCurrent Medicinal Chemistry
Issue number29
Publication statusPublished - 2019

Bibliographical note

Funding Information:
This study was supported by National Research Foundation (NRF) grants (2012M3A9C1053532; 2015M3A6A4065734; and 2018R1A5A2023127).


  • 6-bisphosphatase inhibitors
  • Adenosine 5’-monophosphate
  • Chronic disease
  • Diabetes mellitus
  • Fructose-1
  • Hyperglycemia
  • Type 2 diabetes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry


Dive into the research topics of 'Fructose-1,6-bisphosphatase Inhibitors: A review of recent (2000-2017) advances and structure-activity relationship studies'. Together they form a unique fingerprint.

Cite this